Today: 11 June 2026
Oracle stock in focus for Monday after Morgan Stanley target cut flags AI buildout costs

Oracle stock in focus for Monday after Morgan Stanley target cut flags AI buildout costs

New York, Jan 25, 2026, 10:33 EST — The market has closed.

Oracle shares slipped 0.6% on Friday, finishing at $177.16. The drop followed a price target cut from Morgan Stanley, which cautioned that investors might be underestimating the expenses tied to the company’s push to ramp up AI data-center capacity.

The call hit a shaky tape for big tech, with investors increasingly distinguishing “AI demand” from actual “AI profits.” Oracle stands out in this trade, locking in hefty cloud deals—but it still requires hardware, power, and real estate to fulfill those commitments.

Tension is high this week. The Federal Reserve convenes Jan. 27-28, while earnings reports roll in from Microsoft, Meta, Tesla, and Apple. These results could shift sentiment on cloud spending and capital intensity throughout the sector.

Morgan Stanley’s Keith Weiss highlighted the “significant capital intensity” of the infrastructure buildout and lowered his price target to $213 from $320. He maintained an equal-weight rating, according to Barron’s. Barron’s

Oracle’s recent earnings highlighted the vast scope investors are grappling with. Remaining performance obligations—contracted work still off the books—hit $523 billion, soaring 438% year over year. Finance chief Doug Kehring noted the quarter brought in fresh commitments “from Meta, NVIDIA, and others.” Q4 Investors

January has seen sharp swings in Oracle’s stock. By Friday, shares ended roughly 7% lower than their close on Jan. 16, following a selloff that pushed the price below $180 mid-month.

Oracle handed out a quarterly cash dividend of 50 cents per share on Jan. 23, according to a previous filing — highlighting how shareholder returns are now balancing against an expanding spending cycle.

A potential pitfall for bulls is that the contracts might have slimmer margins than anticipated, or that capacity grows quicker than customer demand, forcing the company to shoulder costs before seeing any revenue. Rising financing expenses would only make that balance riskier.

Oracle’s message to customers is straightforward: it has the supply, can ramp up fast, and supports workloads across multiple clouds. If demand stays steady, investors might tolerate short-term hits to free cash flow.

On Monday, traders will keep an eye on whether the stock can hold above last week’s lows and if tech sentiment remains steady following a volatile Friday that saw major U.S. indexes end largely flat.

After the Fed’s January 28 decision, the spotlight shifts to Oracle’s fiscal third-quarter earnings, slated for mid-March according to its investor-relations FAQ.

Stock Market Today

  • Ford Stock Down 6% Over Five Years Amid Strategic Shift
    June 11, 2026, 10:58 AM EDT. Ford's stock has fallen 6% over five years, significantly underperforming the S&P 500's 71% gain despite a recent 20% rally. The company exited costly electric vehicle (EV) programs, launching Ford Energy to produce lithium-ion phosphate batteries for energy storage through a partnership with China's CATL. Investors remain cautious, focusing on Ford's reliance on domestic sales of its F-Series gas-powered trucks, its longstanding best-seller. Ford's strategic pivot away from EVs, admitting Chinese EV competition risks, and modest international presence contribute to lingering investor skepticism about its long-term value.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
Cloud computing stocks face a packed week as Amazon job cuts loom and Fed meets
Previous Story

Cloud computing stocks face a packed week as Amazon job cuts loom and Fed meets

Tencent stock price: Nvidia H200 chip orders loom as 0700.HK heads into Monday
Next Story

Tencent stock price: Nvidia H200 chip orders loom as 0700.HK heads into Monday

Go toTop